Upcoming IPOs
Industry Offer Price Lot Size Entry Fee Offer Period
Listing Date
No company is about to list for the time being.
2023/01/12 14:18
EVEREST MED-B (01952.HK) snapped a four-day slump and edged up today. The stock once peaked at $23.7 after midday, hitting a new high in six months. It last printed at $22.95, up 21%, on a volume of 8.35 million shares. CICC previously anticipated in a research report that Nefecon, an innovative drug treatment for IgA nephropath...
2023/01/11 11:32
Pharmaceutical stocks edged up today. INNOVENT BIO (01801.HK), which was selected by UBS as one of the sector top picks, mushroomed 8% to $40.6. GENSCRIPT BIO (01548.HK) expanded 7.4% to $27.6. Blue-chip stock WUXI BIO (02269.HK) rebounded 5.9% to post at $71.4, becoming the best-performing blue-chip stock so far in today's ...
2022/12/21 16:32
The HSI settled at 19,160, up 65 pts or 0.3%; the HSCEI lifted 27 pts or 0.4% to 6,500; and the HSTECH climbed 28 pts or 0.7% to 4,024. The full-day turnover shrank to $69.286 billion. As to sportswear, SHENZHOU INTL (02313.HK) spiked 6.7%, being the top gainer among the blue chips and HSCEI constituents, as it is the OEM of Nik...
2022/12/21 10:54
HK-listed pharmaceuticals outpaced the market broadly today. BRII-B (02137.HK), especially, swelled 23% to $9.4. INNOCARE-B (09969.HK), JW THERAP-B (02126.HK), LEPU BIO-B (02157.HK) and KINTOR PHARMA-B (09939.HK) rallied over 2%-3%.Among online medicals, blue chip ALI HEALTH (00241.HK) fared well. It recouped 2.4% to $7.37. Stan...
2022/12/20 16:20
At close, HSI dropped 258 pts or 1.3% to 19,094, falling for two days in a row; HSCEI fell 132 pts or 2%, to close at 6,472; HSTECH fell 128 pts or 3.1% to 3,996. Market turnover reached $96.258 billion.The Hong Kong government announced that the cap on the number of customers allowed at catering premises or banquets will be rem...
2022/12/20 14:13
ASCLETIS-B (01672.HK) further extended its upsurge after midday. Once peaking at $4.92, the stock last stood at $4.84, up 39.88%, on a volume of 41.053 million shares and turnover of $180 million.The company announced that it has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the p...
2022/12/20 11:48
Individual vaccine makers listed in HK fared well today. Among which, CLOVER BIO-B (02197.HK) and ASCLETIS-B (01672.HK) were the top gainers, posting at $3.06 and $4.34, up 14% and 25%. CLOVER BIO had its TP raised by Goldman Sachs to $3.37, whereas ASCLETIS' oral viral polymerase inhibitor was authorized by USPTO. CANSINOBI...
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
You expressly agree that the use of this app/website is at your sole risk. Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party. Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account. Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance. Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor. Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance. Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.